DOPAMINE HCL 0.8MG/ML DEXTROSE 5% INJ USP SOLUTION

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

DOPAMINE HYDROCHLORIDE; DEXTROSE

可用日期:

BAXTER CORPORATION

ATC代码:

C01CA04

INN（国际名称）:

DOPAMINE

剂量:

0.8MG; 50MG

药物剂型:

SOLUTION

组成:

DOPAMINE HYDROCHLORIDE 0.8MG; DEXTROSE 50MG

给药途径:

INTRAVENOUS

每包单位数:

250ML

处方类型:

Prescription

治疗领域:

SELECTIVE BETA 1-ADRENERGIC AGONISTS

產品總結:

Active ingredient group (AIG) number: 0217918001; AHFS:

授权状态:

MARKETED

授权日期:

1992-12-31

产品特点

IMPORTANT: PLEASE READ
_ _
_Appendix E - Product Monograph Template – Standard _
_Template Date: January 2010 _
_Page 1 of 23_
PRODUCT MONOGRAPH
DOPAMINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION, USP
Dopamine Hydrochloride 800, 1600, and 3200 µg/mL and 5% Dextrose
in VIAFLEX Plastic Container
Sympathomimetic
Baxter Corporation
Mississauga, ON
Canada L5N 0C2
Date of Revision:
April 24, 2013
SUBMISSION CONTROL NO: 161802
Baxter and VIAFLEX are trademarks of Baxter International Inc.
IMPORTANT: PLEASE READ
_ _
_Appendix E - Product Monograph Template – Standard _
_Template Date: January 2010 _
_Page 2 of 23_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
5
ADVERSE REACTIONS
...................................................................................................
7
DRUG INTERACTIONS
...................................................................................................
8
DOSAGE AND ADMINISTRATION
...............................................................................
9
OVERDOSAGE
................................................................................................................
11
ACTION AND CLINICAL
PHARMACOLOGY............................................................
11
STORAGE AND STABILITY
.........................................................................................
12
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 12
PART II: SCIENTIFIC INFORMATION
.....................................................................